目次

TABLE OF CONTENT

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 KEY INCLUSIONS & EXCLUSIONS
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.3.3 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.3 MARKET SHARE ESTIMATION METHODOLOGY
2.4 MARKET BREAK DOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE RELATED LIMITATIONS
2.6.2 METHODOLOGY RELATED LIMITATIONS
2.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
2.8 RISK ASSESSMENT
2.9 RECESSION IMPACT ASSESSMENT APPROACH

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 RADIOTHERAPY MARKET: MARKET OVERVIEW
4.1 RADIOTHERAPY MARKET, BY PROCEDURE, 2023 VS 2028
4.1 GEOGRAPHIC ANALYSIS: RADIOTHERAPY MARKET, BY COUNTRY AND REGION (2023)
4.1 GEOGRAPHIC SNAPSHOT OF THE RADIOTHERAPY MARKET

5 MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 MAJOR DRIVERS
5.1.2 KEY RESTRAINTS
5.1.3 KEY GROWTH OPPORTUNITIES
5.1.4 INDUSTRY-SPECIFIC CHALLENGES
5.2 REGULATORY LANDSCAPE
5.2.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.2.2 REGULATORY TRENDS
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM LANDSCAPE
5.6 TECHNOLOGY MAP
5.7 TRADE DATA
5.8 PATENT DATA
5.9 PORTER’S FIVE FORCE ANALYSIS
5.10 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION
5.11 KEY CONFERENCES AND EVENTS IN 2023-25
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 REIMBURSEMENT SCENARIO
5.14 CASE STUDY

6 RADIOTHERAPY MARKET, BY TYPE (USD MILLION; 2021—2028)*
6.1 INTRODUCTION
6.2 PRODUCT
6.3 SOFTWARE &SERVICES

7 RADIOTHERAPY MARKET, BY TECHNOLOGY (USD MILLION; 2021—2028)*
7.1 INTRODUCTION
7.2 EXTERNAL BEAM RADIOTHERAPY (EBRT )
7.2.1 LINEAR ACCELERATORS .
7.2.1.1 CONVENTIONAL LINEAR ACCELERATORS
7.2.1.2 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINEAR ACCELERATORS
7.2.1.2.1 CYBERKNIFE
7.2.1.2.2 GAMMA KNIFE
7.2.1.2.3 TOMOTHERAPY
7.2.1.3 MRI LINEAR ACCELERATORS (MRI-GUIDED ADAPTTIVE RADIOTHERAPY ).
7.2.2 PARTICLE THERAPY SYSTEMS
7.2.2.1 CYCLOTRONS
7.2.2.2 SYNCHROTRON
7.2.2.3 SYNCHROCYCLOTRONS .
7.2.3 CONVENTIONAL COBALT-60 TELETHERAPY UNITS
7.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY
7.3.1 SEEDS
7.3.2 APPLICATORS .
7.3.3 AFTERLOADERS .
7.3.4 INTRAOPERATIVE RADIATION THERAPY (IORT) SYSTEMS .
7.4 SYSTEMIC RADIOTHERAPY
7.4.2 IOBENGUANE (I-131)
7.4.3 SAMARIUM-153
7.4.4 RHENIUM-186
7.4.5 OTHER SYSTEMIC RADIOTHERAPY PRODUCTS .

8 RADIOTHERAPY MARKET, BY APPLICATION USD MILLION; 2021—2028)*
8.1 INTRODUCTION …
8.2 EXTERNAL BEAM RADIOTHERAPY APPLICATION
8.2.1 PROSTATE CANCER
8.2.2 BREAST CANCER .
8.2.3 LUNG CANCER .
8.2.4 HEAD & NECK CANCER .
8.2.5 COLORECTAL CANCER
8.2.6 OTHER CANCERS .
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS
8.3.1 PROSTATE CANCER
8.3.2 GYNECOLOGICAL CANCER
8.3.3 BREAST CANCER .
8.3.4 CERVICAL CANCER .
8.3.5 PENILE CANCER
8.3.6 OTHER CANCERS .

9 RADIOTHERAPY MARKET, BY PROCEDURE (USD MILLION; 2021—2028)*
9.1 INTRODUCTION .
9.2 EXTERNAL BEAM RADIOTHERAPY
9.3.1 IMAGE-GUIDED RADIOTHERAPY (IGRT)
9.3.2 INTENSITY-MODULATED RADIOTHERAPY
9.3.3 3D CONFORMAL RADIOTHERAPY .
9.3.4 STEREOTACTIC THERAPY …
9.3.5 PARTICLE THERAPY ….
9.4 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY .
9.4.1 HIGH-DOSE-RATE BRACHYTHERAPY
9.4.2 LOW-DOSE-RATE BRACHYTHERAPY .
9.4.3 PULSED-DOSE-RATE BRACHYTHERAPY .
9.5 SYSTEMIC RADIOTHERAPY .
9.5.2 INTRAVENOUS RADIOTHERAPY
9.5.3 ORAL RADIOTHERAPY .
9.5.4 INSTILLATION RADIOTHERAPY

10 RADIOTHERAPY MARKET, BY END USER (USD MILLION; 2021—2028)*
10.1 INTRODUCTION….
10.2 HOSPITALS.
10.2 INDEPENDENT RADIOTHERAPY CENTERS.

11 RADIOTHERAPY MARKET, BY REGION (USD MILLION; 2021—2028)*
11.1 NORTH AMERICA
11.1.1 RECESSION IMPACT
11.1.2 US
11.1.3 CANADA
11.2 EUROPE
11.2.1 RECESSION IMPACT
11.2.2 GERMANY
11.2.3 UK
11.2.4 FRANCE
11.2.5 ITALY
11.2.6 SPAIN
11.2.7 REST OF EUROPE
11.3 ASIA-PACIFIC
11.3.1 RECESSION IMPACT
11.3.2 JAPAN
11.3.3 CHINA
11.3.4 INDIA
11.3.5 SOUTH KOREA
11.3.6 AUSTRALIA
11.3.7 REST OF ASIA-PACIFIC
11.4 LATIN AMERICA
11.4.1 RECESSION IMPACT
11.4.2 BRAZIL
11.4.3 MEXICO
11.4.4 REST OF LATIN AMERICA
11.5 MIDDLE EAST AND AFRICA
11.5.1 RECESSION IMPACT

12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.3 REVENUE MAPPNG OF TOP PLAYERS (2022)
12.4 MARKET SHARE ANALYSIS FOR TOP 5 GLOBAL PLAYERS (IN TERMS OF % REVENUE, IN 2022)
12.5 COMPANY EVALUATION MATRIX, 2022
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT
12.6 START-UP/SME EVALUATION MATRIX, 2022
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING
12. 7 COMPETITIVE SCENARIO AND TRENDS (2021-2023)
12.7.1 PRODUCT LAUNCHES
12.7.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
12.7.3 PRODUCT APPROVALS
12.7.4 ACQUISITIONS

13 COMPANY PROFILES**
(Business Overview, Products Offered, Industry-specific Developments for 2021-2023)***
13.1 KEY COMPANIES
13.1.1 SIEMENS HEALTHINEERS AG (VARIAN)
13.1.2 ELEKTA. .
13.1.3 ACCURAY INCORPORATED
13.1.4 IBA .
13.1.5 VIEWRAY TECHNOLOGIES, INC.:
13.1.6 BD.
13.1.7 HITACHI LTD
13.1.8 ICAD, INC.:.
13.1.9 ISORAY, INC.,
13.1.9 SENSUS HEALTHCARE.
13.1.11 SUMITOMO HEAVY INDUSTRIES.
13.1.12 ZEISS GROUP
13.1.13 MEVION MEDICAL SYSTEMS.
13.1.14 INTRAOP MEDICAL, INC.
13.1.15 PHILIPS.
13.1.16 PANACEA MEDICAL TECHNOLOGIES PVT. LTD
13.1.17 P-CURE
13.1.18 PROVISION HEALTHCARE.
13.1.19 SENSUS HEALTHCARE
13.1.20 OPTIVUS PROTON THERAPY, INC.
13.2 OTHER PLAYERS
13.2.1 ISOAID
13.2.2 MAGNETTX ONCOLOGY SOLUTIONS LTD
13.2.3 PROTOM INTERNATIONAL
13.2.4 REFLEXION
13.2.5 S.I.T. SORDINA IORT TECHNOLOGIES S.P.A.
13.2.6 SENSUS HEALTHCARE
13.2.7 ADVANCED ONCOTHERAPY
13.2.8 PTW FREIBURG GMBH
13.2.9 DANFYSIK A/S
13.2.10 BRAINLAB AG

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS